SAR153191 (REGN88)
LTS11210
Phase 3 small_molecule completed
Quick answer
SAR153191 (REGN88) for Rheumatoid Arthritis is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Rheumatoid Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed